natgillin/translations-raw huggingface dataset:
a variable light chain comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 16, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 24, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 22; and a variable heavy chain comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 25, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 14, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 20. The anti-Factor D antibody or antibody fragment of claim 1, wherein the antibody comprises: 
varijabilnu domenu lakog lanca, koja sadrži aminokiselinski slijed SEQ ID NO:11, gdje je CDR1 definiran sa SEQ ID NO:16, CDR2 je definiran sa SEQ ID NO:24, a CDR3 je definiran sa SEQ ID NO:19; i varijabilnu domenu teškog lanca, koja sadrži aminokiselinski slijed SEQ ID NO:12, gdje je CDR1 definiran sa SEQ ID NO:25, CDR2 je definiran sa SEQ ID NO:14, a CDR3 je definiran sa SEQ ID NO:20, gdje su područja varijabilne domene lakog lanca i varijabilne domene teškog lanca izvan CDR područja osnovna, te gdje najmanje jedno osnovno područje ne sadrži niti jednu, ili sadrži jednu, dvije ili tri aminokiselinske zamjene.
EC50 values were derived using Robosage. 
Vrijednosti EC50 dobivene su uz pomoć programa Robosage.
Therefore, neural stem cells having a loss of the CB1 cannabinoid receptor function and neurons obtained from said stem cells may be used as a genetic model for studying upper motor neurodegenerative disorders. METHODS FOR OBTAINING A CORTICOSPINAL UPPER MOTOR NEURON OF THE INVENTION In one aspect, the invention relates to an in vitro method for obtaining a corticospinal upper motor neuron from a neural stem cell, wherein said method comprises contacting a neural stem cell under conditions adequate for increasing the signal mediated by the CB1 cannabinoid receptor in said cells and under conditions to promote dorsalization of said cells. 
PATENTNI ZAHTJEVI In vitro postupak dobivanja kortikospinalnog gornjeg motoričkog neurona iz neuralne matične stanice, naznačen time što se navedeni postupak sastoji u stavljanju u kontakt neuralne matične stanice u uvjetima pogodnim za pojačavanje signala posredovanog kanabinoidnim receptorom CB;, u navedenoj stanici i u uvjetima koji potiču dorzaliziranje navedene stanice, te gdje uvjeti pogodni za pojačavanje signala posredovanog kanabinoidnim receptorom CB, uključuju povećanje broja Ctip2+ Satb2-stanica u odnosu na osnovne razine od najmanje 5% i uključuju:
In particular, the efficacy of rifamicin SV was verified by means of an evaluation of the MIC (Minimum Inhibiting Concentration) on specific pathogenic bacterial strains, such as, for example, Escherichia coli, Enterobacter faecalis, Proteus vulgaris, Pseudomonas aeruginosa, Salmonella typhi and Enterobacter cloacae as shown in the following Table A. 
Posebno je uspješnost rifamicina SV određena određivanjem minimalne inhibitorne koncentracije (MIC) na specifičnim patogenim bakterijskim sojevima kao što su na primjer Escherichia coli, Enterobacter faecalis, Proteus vulgaris, Pseudomonas aeruginosa, Salmonella typhi 1 Enterobacter cloacae, kao što je prikazano u slijedećoj Tablica A. HR P20080252 T3
The formulation of claim 21, wherein the formulation further comprises an adjuvant, the adjuvant being aluminum phosphate. 
Formulacija u skladu s patentnim zahtjevom 22, naznačena time što formulacija dodatno sadrži adjuvans, te što je adjuvans aluminijev fosfat.
The compound for use according to claim 7, wherein the viral infection is yellow fever virus. 
Spoj za uporabu sukladno zahtjevu 7, pri čemu je virusna infekcija virus žute groznice.
This novel salt and crystalline hydrates thereof are useful for the treatment and prevention of diseases and conditions for which an inhibitor of dipeptidyl peptidase-IV is indicated, in particular Type 2 diabetes, obesity, and high blood pressure. 
Ova nova sol i njeni kristalinični hidrati su korisni u liječenju i prevenciji bolesti i stanja za koje je inhibitor dipeptidil peptidaze-IV indiciran, posebno dijabetes tipa 2, pretilost, te visoki krvni tlak.
The process according to any one of the claims 1-8, wherein the thionating agent is used at a molar ratio to the group (I) to be transformed of 1 mole P2S5·2 C5H5N per 1-4 moles of group (I). 
Postupak prema jednom od zahtjeva 1 do 8, naznačen time, da se tionacijsko sredstvo upotrebljava u molarnom odnosu prema skupini (I) koja se pretvara, kao 1 mol od P2S5•2C5H5N prema 1 do 4 mola od skupine (I).
The method of any of claims 1 - 7 wherein the silica binder is at 6 wt % to 12 wt % of the dry weight of the first set of components. 
Metoda iz bilo kojeg od patentnih zahtjeva 1-7 pri čemu je silicijevo vezivo 6 wt% do 12 wt% suhe težine prvog seta komponenata.
A process according to claim 5 for the manufacture of a salt of escitalopram characterised in that the escitalopram free base is precipitated from a crude escitalopram. 
Postupak prema zahtjevu 16 za proizvodnju soli escitaloprama, naznačen time, što slobodna baza escitaloprama precipitira iz sirovog escitaloprama. t>&
a first cog wheel (12) mobile in rotation (R 1) in relation to the support (2) around a first axis (A 1); 
- prvi zupčanik (12) koji se okreće (R1) u odnosu na nosač (2) oko prve osovine (A1);
a cyclic peptide formable or formed by an amino acid sequence as encoded by a nucleotide sequence as depicted in any one of SEQ ID NO. 
Ciklički peptid u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što ima aminokiselinski slijed Asp-Glu-Ala-Arg-Arg-Cys-Tyr-Asn-Asp-Pro-Lys; ili Glu-Ser-Asp-Glu-Ala-Arg-Arg-Cys-Tyr-Asn-Asp-Pro-Lys.
The netrin-1 binding polypeptide of any one of claim 5 to 9, which comprises an amino acid sequence selected from the group of SEQ ID NO: 14 to 19 and/or from the group of SEQ ID NO: 20 to 27, preferably it comprises an amino acid sequence selected from the group of SEQ ID NO: 14 to 19 and an amino acid sequence selected from the group of SEQ ID NO: 20 to 27. 
Monoklonsko protutijelo koje veže netrin-1 prema bilo kojem od zahtjeva 8 do 11, naznačeno time što sadrži aminokiselinsku sekvencu odabranu iz skupine SEQ ID NO: 14 do 19 i/ili iz skupine SEQ ID NO: 20 do 27, poželjno sadrži aminokiselinsku sekvencu odabranu iz skupine SEQ ID NO: 14 do 19 i aminokiselinsku sekvencu odabranu iz skupine SEQ ID NO: 20 do 27.
The layer sequence repeater module of claim 9, wherein the cell of axially disposed thin annular disks comprises two of said sequences in reverse order. 
Modul za ponavljanje niza slojeva u skladu s patentnim zahtjevom 9, naznačen time što ćelija (30) aksijalno smještenih tankih prstenastih diskova sadrži dva navedena niza u suprotnom redoslijedu.
preparing an aqueous solution comprising 3-10% whey protein, a pH value of 7 to 9, wherein the calcium concentration of the whey protein is 1.4 mM or less or has been reduced at least 50%, more preferably at least 98%; 
(vi) pripremu vodene otopine koja sadrži 3 do 10% proteina sirutke, ima pH vrijednost od 7 do 9, a koncentracija kalcija u proteinu sirutke iznosi 1.4 mM ili manje ili je smanjena za barem 50%, poželjnije za barem 98%;
Process according to claim 1, characterised in that the volume occupied by the frustoconical section with respect to the total volume of the particle bed is equal in percentage to angle B of the frustoconical section measured in degrees. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je volumen zauzet odjeljkom u obliku krnjeg stošca u odnosu na ukupni volumen sloja čestica jednak u postocima kutu B odjeljaka u obliku krnjeg stošca izmjerenog u stupnjevima.
In this regard, in a particular embodiment, the compositions of the invention may further comprise at least one compound selected from Sulfisoxazole, Methimazole, Prilocaine, Dyphylline, Quinacrine, Carbenoxolone, Aminocaproic acid, Cabergoline, Diethylcarbamazine, Cinacalcet, Cinnarizine, Eplerenone, Fenoldopam, Leflunomide, Levosimendan, Sulodexide, Terbinafine, Zonisamide, Etomidate, Phenformin, Trimetazidine, Mexiletine, Ifenprodil, Moxifloxacin, Bromocriptine or Torasemide. 
Smjesa za uporabu prema zahtjevu 1, dalje sadrži barem jedan dodatni spoj izabran iz grupe koja obuhvaća sulfizoksazol, metimazol, prilokain, difiln, kvinakrin, karbenoksolon, aminokaproičnu kiselinu, kabergolin, dietilkarbamazin, sinakalcet, cinarizin, eplerenon, fenoldopam, leflunomid, levosimendan, sulodeksid, terbinafin, zonisamid, etomidat, fenformin, trimetazidin, meksiletin, ifenprodil, moksifloksacin, bromokriptin ili torasemid, ili njihove farmaceutski prihvatljive soli.
The resulting mixture was stirred at room temperature for 16h, evaporated to dryness, dissolved in ethanol and evaporated to dryness to give 17.56g of pure compound as a brown solid. 
Dobivenu smjesu miješa se 16 sati na sobnoj temperaturi, otpari do suhog, otopi u etanolu, te otpari do suhog kako bi se dobilo 17,56 g čistog spoja u obliku smeđe krutine.
xxix) said in vitro -synthesized RNA contains one or more modified ribonucleosides, selected from the group consisting of pseudouridine, 1-methylpseudouridine, 5-methyluridine, 2'-O-methyluridine, 2-thiouridine, and 5-methylcytidine in place of at least a portion of the corresponding unmodified canonical ribonucleoside; and/or 
Obrađeni sastav ribonukleinske kiseline u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što navedeni sastav ribonukleinske kiseline ili ssRNA ili mRNA kodira najmanje jedan protein odabran iz skupine koja se sastoji od:
a first stream of boil-off gas, which is generated from the liquefied natural gas in the storage tank and is discharged from the storage tank; 
prvu struju otparenog plina, koju se dobiva iz ukapljenog prirodnog plina u spremniku za teret (11), te ispušta iz spremnika za teret (11);
The reaction mixture was cooled to 18°C and 3N HCl (300mL) was added until the solution was acidic (pH=1). 
Reakcijska se smjesa ohladi na 18 *C i doda se 3N HCI (300 mL) dok otopina ne postane kisela (pH = 1).
The method according to claim 12, wherein the insertion site is located between two adjacent amino acids at a position between amino acids 570 and 611 of VP1 of AAV2 or the corresponding position in the capsid protein of another AAV serotype. 
Virion rAAV prema patentnom zahtjevu 7, naznačen time što je mjesto umetanja unutar aminokiselina 587-588 AAV2 kapsidnog proteina navedeno u SEQ ID NO:1 ili unutar odgovarajućeg položaja u kapsidnom proteinu drugog AAV serotipa.
A pharmaceutical composition comprising droxidopa in combination with one or more additional compounds selected from the group consisting of: 
Farmaceutski sastav, prema zahtjevu 1, naznačen time da je u njemu jedan ili više dodatnih spojeva odabrano iz grupe koja se sastoji od entakapona, tolkapona, piridostigmina. donepezila i njihovih kombinacija.
an active substance selected from the group consisting of antibodies directed against VEGF, VEGFR or soluble VEGFR/VEGFR hybrids, and tyrosine kinase inhibitors, and 
(i) aktivnu tvar koju se bira iz skupine koju čine protutijela usmjerena protiv VEGF-a, VEGFR-a ili topljivih hibrida VEGFR/VEGER, te inhibitori tirozinskih kinaza, i
The method according to claim 6, wherein the hydrophilic gelling agent is selected from at least one of glucose, modified starch, methyl cellulose, carboxymethyl cellulose, propyl cellulose, hydroxypropyl cellulose, a carbomer polymer, alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, agar, carrageenan, locust bean gum, pectin, and gelatin. 
Pripravak prema zahtjevu 1 ili 2, koji dalje sadrži barem jednu hidrofilnu gelirajuću tvar, odabranu između glukoze, modificiranog škroba, metil celuloze, karboksimetil celuloze, propil celuloze, hidroksipropil celuloze, karbopol® polimera, alginatne kiseline, natrijevog alginata, kalijevog alginata, amonijevog alginata, kalcijevog alginata, agara, karagenana, karuba gume, pektina i želatine.
insertion of a reporter gene operably linked to a promoter active in a rat cell. 
reporter gen operativno povezan s promotorom aktivnim u stanici štakora
The use of a material according to any of claims 1-13 for thermal and/or acoustic insulation and/or acoustic and/or vibration damping insulation and/or fire protection insulation in indoor and outdoor applications. 
Upotreba materijala u skladu s bilo kojim od patentnih zahtjeva 1-12, naznačena time što je materijal namijenjen toplinskoj i/ili zvučnoj izolaciji i/ili zvučnoj i/ili izolaciji za prigušivanje vibracija i/ili izolaciji za zaštitu od požara u interijerima i eksterijerima.
to 40 %, preferably 10-40% by weight of disintegrant, and optionally 
1 do 40 %, poželjnije 10-40 % masenog udjela razgrađujućeg sredstva, i izborno
using an oligonucleotide comprising or consisting essentially of the sequence of SEQ ID NO: 7 in item (i); and 
oligonukleotid od (2) obuhvatć ili se sastoji od sekvence SEK ID BR: 7 ili njene inačice; i
In order to achieve an even more improved stability, it is provided that positive and/or negative charge carriers are incorporated into the first layer after producing the first layer. 
Solarna ćelija u skladu s u najmanju ruku patentnim zahtjevom 1, naznačena time što pozitivni i/ili negativni nosioci naboja su ugrađeni u prvi sloj (22) nakon dobivanja prvog sloja.
0.334 0.391 An orally administrable pharmaceutical composition comprising a, a, a -trifluorothymidine and 5-chloro-6-(2-iminopyrrolidine-1-yl) methyl-2,4 (1H,3H)-pyrimidine dione hydrochloride as active ingredients and a sugar having a critical relative humidity of 85% or more at 25°C as an excipient. 
Farmaceutska kompozicija koja se može oralno administrirati koja sadrži a,0,0-trifluorotimidin i 5-kloro-6-(2- iminopirolidin-1-il) metil-2,4 (1H,3H)-pirimidin dion hidroklorid kao aktivne sastojke i šećer koji ima kritičnu relativnu vlažnost od 85% ili više na 25C kao ekscipijens, i koja sadrži djelomično predželatinizirani škrob kao agens za raspadanje, gdje je sadržaj agensa za raspadanje od 2 do 16% mase u ukupnoj količini farmaceutske kompozicije.
if said steps of changing and removing occur in a same station, said electrically conducting fluid (8) and said fluid jet (9) for removing the fragments (30) are mixed according to a determined ratio, such that the stations are simpler and the fragments (30) removal is more efficient. 
Postupak prema zahtjevu 1, naznačen time da navedeni korak promjene omogućava da se navedeni spremnici urone u vanjsko električno polje, te naročito uzrokuje da navedeni spremnici prolaze između nasuprotnih površina ravnog paralelnog električnog kondenzatora; te se naročito navedeno električno polje naizmjence prebacuje između višestrukih polariteta tako da je sila elektrostatske adhezijske koja djeluje na navedene komadiće i navedene spremnike privremeno smanjena ili poništena, te se naročito navedeni koraci promjene i uklanjanja odvijaju u istoj postaji, tj.
The window according to claim 1, the frame includes at least one hinge slot in the side wall of the sill channel for allowing the first part of the hinge to pass at least partially out of the sill channel as the casement is opened. 
Prozor prema zahtjevu 7, naznačen time da podestna letvica obuhvaća bočni zid (92) za smanjenje širine odgovarajućeg kanala na način da je otprilike jednak širini drugog dijela (172).
Additionally, the method can further comprise administering another anti-cancer treatment to said mammal The anti-cancer treatment is selected from the group consisting of an anti-angiogenesis agent, a chemotherapeutic agent, and an anti-neoplastic agent. 
Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 11, naznačeno time što se navedeno antikancerozno liječenje bira iz skupine koju čine antiangiogenetsko sredstvo, kemoterapijsko sredstvo i antineoplastično sredstvo.
An oral formulation according to claim 8 wherein the ocular neovascular disorder is exudative age-related macular degeneration (AMD), angiod streaks, pathological myopia, ocular histoplasmosis syndrome, breaks in Bruch's membrane, macular edema (including diabetic macular edema), sarcoidosis, uveitis, atrophic AMD, keratoconus, Sjogren's syndrome, myopia, ocular tumors, corneal graft rejection, corneal injury, neovascular glaucoma, corneal ulceration, corneal scarring, proliferative vitreoretinopathy, retinopathy of prematurity, retinal degeneration, chronic glaucoma, retinal detachment, or sickle cell retinpathy. 
Upotreba u skladu s patentnim zahtjevom 23, naznačena time što neovaskularni poremećaj oka je eksudativna staračka degeneracija makule (AMD), angiodne strije, patološka miopija, sindrom histoplasmoze oka, rupture Bruchove membrane, makularni edem (uključujući dijabetični makularni edem), sarkoidoza, uveitis, atrofični AMD, keratokonus, Sjogrenov sindrom, miopija, tumori oka, odbacivanje presađene rožnice, ozljeda rožnice, neovaskularni glaukom, ulceracija rožnice, ožiljavanje rožnice, proliferativna vitreoretinopatija, prematurna retinopatija, degeneracija mrežnice, kronični glaukom, odljuštenje rožnice ili drepanocitozna retinpatija.
The compound according to claim 1 wherein R1 is Me, Et or is selected from a group of the following Formulae: 
Spoj prema zahtjevu 1, 2 ili 3, naznačen time, da R' je Me, Et, ili je odabran iz skupine od sljedećih Formula:
The composition for use according to claim 1, wherein the therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof is administered three times or more a day for as long as the subject is in need of treatment for acute myeloid leukemia (AML). 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 1, pri čemu se terapeutski djelotvorna količina crenolaniba ili njegove farmaceutski prihvatljive soli daje tri ili više puta dnevno sve dok je subjektu potrebno liječenje akutne mijeloične leukemije (AML).
A conjugate comprising an antibody of claim 1 coupled to a therapeutic agent. The conjugate of claim 19, wherein the therapeutic agent is a toxin, a radioisotope, a drug or a cytotoxic agent. 
Konjugat koji se sastoji od antitijela suglasno bilo kojem zahtjevu 1-11, povezanog sa nekim terapeutskim agensom, poželjno toksinom ili radioizotopom, lijekom ili nekim citotoksičnim agensom.
According to the present invention the outer surface of the capsule 1 presents a dedicated sealing member (sealing material) 8. 
U skladu s predmetnim izumom vanjska površina čahure 1 predstavlja namjenski element za nepropusno zatvaranje (materijal za brtvljenje) 8.
The column (19×7 cm) was eluted with 3% CH3CN in water and the fractions (approx. 100 ml) were analyzed by TLC. 
Kolona (19 x 7 cm) je eluirana s 3% CHgCN u vodi i frakcije (približno 100 mL) su analizirane
is halogen, subsituted or unsubstitued alkyl, substituted or unsubstituted alkenyl, subsituted or unsubstitued alkynyl, subsituted or unsubstitued cycloalkyl, subsituted or unsubstitued aryl, subsituted or unsubstitued heteroaryl, subsituted or unsubstitued heterocyclyl, oxo, -CN, -OR', -NR'R", -COR', -CO2R', -CONR'R", -C(=NR')NR"R"', -NR'COR",-NR'CONR'R", -NR'CO2R", -SO2R', -SO2aryl, -NR'SO2NR"R"', or -NR'SO2R", wherein R', R", and R"' are independently hydrogen, halogen, subsituted or unsubstitued alkyl, substituted or unsubstituted alkenyl, subsituted or unsubstitued alkynyl, subsituted or unsubstitued cycloalkyl, subsituted or unsubstitued aryl, subsituted or unsubstitued heteroaryl, subsituted or unsubstitued heterocyclyl, wherein (R' and R"), and/or (R and R"') together with the atoms to which they are attached, can form a ring selected from cycloalkyl, saturated or unsaturated heterocycle, aryl, and heteroaryl rings. 
je halogen, supstituirani ili nesupstituirani alkil, supstituirani ili nesupstituirani alkenil, supstituirani ili nesupstituirani alkinil, supstituirani ili nesupstituirani cikloalkil, supstituirani ili nesupstituirani aril, supstituirani ili nesupstituirani heteroaril, supstituirani ili nesupstituirani heterociklil, okso, -CN, -OR', -NR'R", -COR', -CO2R', -CONR'R", -C(=NR')NR"R"', -NR'COR",-NR'CONR'R", -NR'CO2R", -SO2R', -SO2aril, -NR'SO2NR"R"', ili -NR'SO2R", gdje su R', R", i R"' nezasivno vodik, halogen, supstituirani ili nesupstituirani alkil, supstituirani ili nesupstituirani alkenil, supstituirani ili nesupstituirani alkinil, supstituirani ili nesupstituirani cikloalkil, supstituirani ili nesupstituirani aril, supstituirani ili nesupstituirani heteroaril, supstituirani ili nesupstituirani heterociklil, gdje (R' i R"), i/ili (R i R"') zajedno s atomima na koje su spojeni, mogu formirati prsten odabran između cikloalkila, zasićenog ili nezasićenog heterocikla, arila, i heteroarilnih prstenova.
The method according to claim 6 wherein said further administration(s) is (are) simultaneous, separate or sequential with that of inecalcitol. 
Inekalcitol, namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što jedna ili više navedenih dodatnih primjena su istodobne, odvojene ili uzastopne onoj inekalcitola.
The method of claim 7 wherein the crop is corn, rice, sorghum, barley or rye. 
Metoda iz zahtjeva 7, naznačena time, što je usjev kukuruz, riža, sirak, ječam ili raž.
or pharmaceutically acceptable salts thereof, and a therapeutically effective amount of a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein: 
terapijski efikasne količine spoja sa formulom II: [image] ili farmaceutski prihvatljive soli tog spoja, gdje:
Ethyl acetate (100 mL) was added and the organic phase was washed with water (50 mL) and brine (50 mL). 
Doda se etil acetat (100 ml) i organska faza se ispere s vodom (50 ml) i fiziološkom (50 ml).
Wind system (1) according to claim 4, characterised in that said systems that actuate said spoiler are piezoelectric. 
Vjetreni sustav (1) prema zahtjevu 5, naznačen time da spomenutim permanentnim magnetima pomažu superprovodljive zavojnice.
activates the adaptive immune response by regulating the induction and/or expression of genes associated with T-cell regulation; or 
aktivira adaptivni imuni odgovor i regulira indukciju i/ili ekspresiju gena povezanih sa regulacijom T-ćelija; ili
A polynucleotide comprising a coding portion encoding a polypeptide consisting of a coagulation factor and one to five human chorionic gonadotropin carboxy terminal peptides (CTPs) attached to the carboxy terminus of said coagulation factor, wherein said coagulation factor is Factor VII, and wherein the sequence of said CTPs comprises the first 10 amino acids of SEQ ID NO: 4. 
Polinukleotid koji sadrži kodirajući dio koji kodira polipeptid koji se sastoji od faktora koagulacije i pet ljudskih korionskih gonadotropinskih karboksi terminalnih peptida (CTP-ova) vezanih na karboksi terminalni kraj navedenog faktora koagulacije, pri čemu navedeni faktor koagulacije je Faktor VII ili Faktor VIIa, ili kodirajući dio koji kodira polipeptid koji se sastoji od faktora koagulacije i tri ljudska korionska gonadotropinska CTP-a vezana na karboksi terminalni kraj navedenog faktora koagulacije, pri čemu navedeni faktor koagulacije je Faktor IX, pri čemu sekvenca navedenih CTP-ova sadrži prvih 10 amino kiselina iz SEQ ID NO: 4.
The compound 2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-ene-1-carbaldehyde or a pharmaceutically acceptable salt thereof. 
Spoj, naznačen time, da je 2-(4-klorofenil)-5,5-dimetilcikloheks-1-en-1-karbaldehid ili njegova farmaceutski prihvatljiva sol.
The method of claim 2, wherein the timolol is administered topically in a medicament selected from the group consisting of ointments, creams, gels, lotions, patches, and foams. 
Uporaba patentnih zahtjeva 1-8, naznačena time, da je lijek u obliku odabranom iz skupine koja se sastoji od zrnaca, praška, granula, raspršivača, transdermalnih naljepaka, krema, losiona i otopina za grgljanje (kolirij).
Aspect 7. The system of aspect 5 wherein the electric heater has a maximum dimension perpendicular to its length that varies. 
Sustav (10) prema zahtjevu 5, pri čemu električni grijač (14) ima vertikalnu dimenziju u odnosu na njegovu dužinu, koja varira.
A compound of formula (I): wherein X is oxygen, sulphur, NH, NOH, or NOMe; 
Spoj s formulom (I): naznačen time što X je kisik, sumpor, NH, NOH ili NOMe;